T
TREVI THERAPEUTICS INC
NASDAQ: TRVI (Trevi Therapeutics, Inc.)
Last update: 4 hours ago14.41
0.22 (1.55%)
| Previous Close | 14.19 |
| Open | 14.00 |
| Volume | 898,764 |
| Avg. Volume (3M) | 1,489,047 |
| Market Cap | 2,045,164,928 |
| Price / Book | 10.66 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -0.450 |
| Total Debt/Equity (MRQ) | 0.96% |
| Current Ratio (MRQ) | 15.38 |
| Operating Cash Flow (TTM) | -41.27 M |
| Levered Free Cash Flow (TTM) | -24.53 M |
| Return on Assets (TTM) | -34.41% |
| Return on Equity (TTM) | -55.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Trevi Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
2.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.25 |
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 79.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Eventide Asset Management, Llc | 31 Dec 2025 | 2,622,306 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (HC Wainwright & Co., 45.73%) | Buy |
| Median | 20.00 (38.79%) | |
| Low | 19.00 (D. Boral Capital, 31.85%) | Buy |
| Average | 20.00 (38.79%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 11.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 09 Mar 2026 | 19.00 (31.85%) | Buy | 11.70 |
| HC Wainwright & Co. | 09 Mar 2026 | 21.00 (45.73%) | Buy | 11.70 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |